The U.S. Patent and Trademark Office has issued a patent for human embryonic stem cell derived mesenchymal stem cells, called hES-T-MSC or T-MSC, and for their method of production.
ImStem Biotechnology, Inc.(ImStem) announced today it has successfully treated an animal model of multiple sclerosis (MS) using human embryonic stem cells (hESC) derived mesenchymal stem cells (MSCs), called hES-MSCs.
ImStem Biotechnology, (ImStem) announced today that Dr. Hongkui Deng, Ph.D. has been appointed to the Company's Scientific Advisory Board.
ImStem Biotechnology’s Drs. Xiaofang Wang and Ren-He Xu were awarded $1.1 million in state stem cell funding.
“ImStem's work is not only important from a public health standpoint, but is part of a wider growing biotech industry that is creating well-paying, high-tech jobs,” said Mike Demicco (D-Farmington).
The FDA has lifted the clinical hold and cleared the investigational new drug (IND) application to assess IMS001 in the treatment of multiple sclerosis (MS).
